Pluristem Demonstrates The Potential Of Its PLX Cells To Treat Crohn's Disease And Ulcerative Colitis

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced that the Company's PLacental eXpanded (PLX) cells have demonstrated in vivo efficacy in the treatment of Crohn's Disease and Ulcerative Colitis, collectively termed Inflammatory Bowel Disease (IBD).

Cimzia reg; Approved In United States For Crohn's Disease

According to a press release from UCB on April 22, 2008, a newpegylatedanti-TNF^I, will be made available in the United States under thename Cimzia in the next few days. This will be a new, promising option for patients suffering from moderate to severe Crohn'sDisease.

FDA Approval Of Cimzia R For Crohn's Disease Represents Latest Milestone For Nektar's PEGylation Technology Platform

The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy.

FDA Approves Cimzia To Treat Crohn's Disease

A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies.

Omega-3's No Help For Crohn's Sufferers

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease. The research is published in the April 9 Journal of the American Medical Association.

For Crohn's Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse

Administrationof omega-3 fatty acid supplements did not appear to improve the rate ofrelapse in patients with Crohn's disease, according to a study releasedon April 9, 2008 in JAMA. Crohn'sDisease is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.

Abbott Presents Long-term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA reg; adalimumab Maintained Remission

Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations at Digestive Disease Week (DDW) in San Diego.

HUMIRA Improves Remission In Crohn's Patients

An open-label extension study of the CHARM and GAIN studies, performedin Abbott labs, demonstrate that patients with moderate-to-severeCrohn's disease who are treated with HUMIRA (adalimumab) actually achieved long-term clinical remission and a fullclinical response respectively.

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA R Adalimumab Maintained Remission

Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations at Digestive Disease Week(R) (DDW) in San Diego.

Bacteria In Cows' Milk May Cause Crohn's Disease

Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea.The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.